Re-Thinking Oncology HTAs: the (Growing) Role of Non-OS Endpoints
Published: | Updated:
Cancer patients’ journeys are complex and the benefit of a drug goes well beyond survival, even in cases of incurable and/or metastatic cancer.
Mattia Belloni
Advertisement
Articles by Mattia Belloni
Advertisement
Latest Updated Articles
Re-Thinking Oncology HTAs: the (Growing) Role of Non-OS EndpointsPublished: June 23rd 2025 | Updated: June 24th 2025
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Hernexeos Under National Priority Voucher Program
2
Pharmaceutical Executive Daily: FDA Approves Hernexeos
3
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
4
Bringing HIV Prevention DTC: Q&A with Ashley Gildea
5